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Acid-labile sulfurHydrogen sulﬁde (H2S) is gaining acceptance as a signaling molecule and has been shown to elicit a variety of
biological effects at concentrations between 10 and 1000 μmol/l. Dissolved H2S is a weak acid in equilibrium
with HS− and S2− and under physiological conditions these species, collectively referred to as sulﬁde, exist in
the approximate ratio of 20% H2S, 80% HS
− and 0% S2−. Numerous analyses over the past 8 years have
reported plasma or blood sulﬁde concentrations also in this range, typically between 30 and 300 μmol/l, thus
supporting the biological studies. However, there is some question whether or not these concentrations are
physiological. First, many of these values have been obtained from indirect methods using relatively harsh
chemical conditions. Second, most studies conducted prior to 2000 failed to ﬁnd blood sulﬁde in micromolar
concentrations while others showed that radiolabeled 35S-sulﬁde is rapidly removed from blood and that
mammals have a relatively high capacity to metabolize exogenously administered sulﬁde. Very recent studies
using H2S gas-sensing electrodes to directly measure sulﬁde in plasma or blood, or HPLC analysis of head-
space gas, have also indicated that sulﬁde does not circulate at micromolar levels and is rapidly consumed by
blood or tissues. Third, micromolar concentrations of sulﬁde in blood or exhaled air should be, but are not,
malodorous. Fourth, estimates of dietary sulfur necessary to sustain micromolar levels of plasma sulﬁde
greatly exceed the daily intake. Collectively, these studies imply that many of the biological effects of sulﬁde
are only achieved at supra-physiological concentrations and they question whether circulating sulﬁde is a
physiologically relevant signaling molecule. This review examines the blood/plasma sulﬁde measurements
that have been reported over the past 30 years from the perspective of the analytical methods used and the
potential sources of error.© 2009 Elsevier B.V. All rights reserved.Within the past decade the scientiﬁc community has changed its
opinion of hydrogen sulﬁde (H2S) from noxious and toxic gas to a
biologically relevant signaling molecule, i.e., a gasotransmitter [71].
Gasotransmitters must fulﬁll several criteria including an ability to
stimulate appropriate effector systems, synthesis or release of the signal
that is initiated by physiological stimuli, and the gasotransmitter must
producebiological responses atphysiologically relevant concentrations.
Considerable evidence has accumulated to support at least the ﬁrst of
these criteria. Sulﬁde (used in this review todenote the sumofdissolved
H2S andHS−; seebelow)hasbeenshowntobestimulatoryor inhibitory
in neurological, cardiovascular, gastrointestinal, genitourinary and
endocrine systems and it may have additional modulatory and/or
cytoprotective effects [36,41,45,58,65]). Sulﬁdehas beenproposed to be
both pro- and anti-inﬂammatory [39,70] and it has even been reported
to induce suspended animation in mice [3]. In the mammalian cardio-
vascular system sulﬁde dilates systemic [23] and constricts pulmonary
[52] vessels. Sulﬁde has been shown to have protective effects in the
heart and brief exposures to endogenous sulﬁde provides a precondi-
tioning effect protecting the heart against ischemia reperfusion injury
[2,4,16]. In non-mammalian systems it variously constricts, dilates orll rights reserved.has multiphasic effects on systemic and respiratory vessels [15]. Nearly
all of the effects of exogenous sulﬁde have been observed at sulﬁde
concentrations in the tens to hundreds of μmol/l.
Sulﬁde is produced in many, if not all, tissues by two cytosolic
pyridoxyl 5′phosphate-dependent enzymes, cystathionine β-
synthase (CBS, EC 4.2.1.22) and cystathionine γ-lyase (CSE; a.k.a.
CGL and cystathionase, EC 4.4.1.1; reviewed in [32,41,65]). It has
recently been shown that mitochondrial, 3-mercaptopyruvate sulfur
transferase (3-MPST; EC 2.8.1.2) is important in sulﬁde synthesis in
the brain [60].
Numerous studies in the past decade have reported sulﬁde
concentrations in cerebral spinal ﬂuid, blood and tissues that are
also in the ten to several hundred μmol/l. These values have been used
to justify the above mentioned biological studies and satisfy the
criteria for sulﬁde as a gasotransmitter. They also suggest a high level
of tonic activity of this system. This exuberance has overlooked a few
practical aspects of sulﬁde chemistry andmetabolism. First, there is no
obvious odor of H2S gas in blood or exhaled alveolar air even though
micromolar sulﬁde concentrations in blood should result in H2S
concentrations in exhaled air that can be detected by the human nose
[18,75]. In fact, these sulﬁde concentrations are within the range of
those reported for human ﬂatus [37]. Second, Furne et al. [18]
predicted that the high level of sulﬁde production necessary to sustain
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a rate nearly 100 times greater than the daily requirement of cysteine
and methionine combined.
Recent studies employing different analytical techniques have not
veriﬁed micromolar concentrations of sulﬁde in either blood [61,75] or
tissue [18,26]. This raises the question whether sulﬁde can exist in the
circulation as an endocrine-like signal and, perhaps more importantly, if
the sulﬁde concentrations employed inmanybiological studies are indeed
physiologically relevant. The purpose of this brief review is to brieﬂy
evaluate thepotential for sulﬁde to serveas ablood-bornebiological signal
from the perspective of themolecular forms of sulﬁde potentially present
in blood and the methods utilized to identify these forms.
1. Forms of hydrogen sulﬁde
1.1. “Free” sulﬁde
Dissolved H2S gas is a weak acid and in solution exists in the
equilibrium H2S↔HS−↔S2−. With the pKa1 ∼7.0 and the pKa2N17
[14,51,54] there is essentially no S2− in biological tissues, nearly equal
amounts of H2S and HS− within the cell, and approximately a 20%
H2S/80% HS− ratio in extracellular ﬂuid and plasma at 37 °C and pH
7.4. Because of the temperature sensitivity of pKa1, the H2S/HS− ratio
remains nearly constant in blood and tissues of ectothermic
vertebrates over a wide range of body temperatures, e.g., in trout
blood at 10 °C the ratio is 15% H2S/85% HS− [14,51]. Often for
convenience H2S, HS− and S2− are referred to as “H2S”, although it is
perhaps more appropriate to refer to these species collectively as
either “sulﬁde” or “total free sulﬁde”.
1.2. “Bound” sulﬁde
A number of mechanisms have also been described in which
sulﬁde can be reversibly “bound” to other molecules and released at a
later date. In this way it may be possible to store or transport sulﬁde in
a less labile, non-gaseous state. There is a broad range of sulfur atoms
covalently bound to another sulfur atom to form sulfane sulfur.
Sulfane sulfur originates in vertebrates from the anaerobic metabo-
lism of cysteine (Cys) by enzymes that include CBS, CSE and 3-MPST
(following deamination of Cys to 3-mercaptopyruvate) and rhodanese
(2.8.1.1) and exists in a variety of forms including thiosulfate,
persulﬁdes, thiosulfonate, polysulﬁdes, polythionate and elemental
sulfur [25,68,69]. A variety of sulfane sulfur compounds are often
generically termed acid-labile sulfur, non-acid labile sulfur, bound
sulfur, tissue-bound sulfur, sulﬁde liberated by dithiothreitol, and
protein-bound or protein-associated sulfur. These labels originated
from the conditions under which the sulﬁdewas released [25,69]. This
nomenclature is often confusing; for example, Ubuka [69] and Tanabe
[66] make a distinction between acid-labile and sulfane sulfur (the
latter liberating sulﬁde when exposed to reducing agents), whereas
Iciek and Włodek [25] include the acid-labile sulfur as sulfane sulfur.
Acid-labile sulﬁde is derived primarily, but not exclusively from
iron-sulfur centers in mitochondrial enzymes. It is released under
acidic (pHb5), and therefore generally produced under non-physio-
logical conditions. Typically, acid-labile sulﬁde is assayed colo-
rimetrically with the methylene blue method or following evolution
of H2S into head-space gas and gas chromatography [69].
Sulﬁde is released frombound sulfane sulfur by reducing conditions
such as excess reduced glutathionine (GSH), Cys [68], dithiothreitol
(DTT; [73]) or by a combination of Cys and GSH [26]. In the cell this is
favored by alkaline conditions and this has been used as an additional
criterion to distinguish this form of sulfur from acid-labile sulfur [26].
Sulfane sulfur is most often quantiﬁed by cold cyanolysis and
colorimetric measurement of ferric thiocyanate or by direct measure-
ment of evolved H2S into head-space gas and subsequent gas
chromatography [69,76], although this is reported to have limitedsensitivityand speciﬁcity [25]. Iciek andWłodek [25] alsopointout that
the different methods employed to release sulﬁde from bound sulfur
may release sulﬁde fromdifferent stores and are often not all inclusive.
The relationship between acid-labile sulﬁde and sulﬁde derived
from bound sulfur has been most extensively characterized by
Ishigami et al. [26]. Acid-labile sulﬁde was not released from
homogenates of the brain, heart or liver until pH fell below 5.4 and
in all instances the amount of sulﬁde released was greatest at pH 1.5
(∼160 nmol/g protein from the brain and heart and 430 nmol/g
protein from the liver). Essentially all acid-labile sulﬁde originated
from the mitochondrial fraction and approximately 30 min were
required for the maximal rate of sulﬁde release by acid. It was also
observed that acid-labile sulﬁde was speciﬁcally released from brain
homogenates by the detergent sodium dodecylsulfate (SDS) and by
guanidine. Sulﬁde from bound sulfur was released by 5 mmol/l DTT
from rat brain and liver, but not the heart. Maximum sulﬁde release
occurred between 1 and 2 h in the liver (nearly 6 μmol/g protein)
whereas the rate of sulﬁde release by DTT in the brain continued to
increase over the 5 h experiment, up to nearly 2 μmol/g protein.
Release of acid-labile sulﬁde was not affected by DTT, nor was release
of sulfane sulfur affected by HCl. Exogenous sulﬁde (as Na2S) was
rapidly “absorbed” by the liver and heart (≤10 min) and absorbed by
the brain over 30 min. Sulﬁde was not absorbed by bovine serum
albumin, lysozyme, and only slowly by fetal bovine serum. The sulﬁde
absorbed by the brain appeared to be conﬁned to the DTT-labile store
andwas notmobilized by acid, SDS or guanidine. Sulfane sulfur sulﬁde
was also released from mouse brain homogenates by mixtures of Cys
and GSH at physiological concentrations (0.1 and 10, or 0.25 and
10 mmol/l, respectively), whereas graded concentrations of Cys (0.1–
0.25 mmol/g protein) or GSH (3–10 mmol/g protein) alone, or in
other combinations, were ineffective. Nearly all of the sulfane sulfur
was found in the cytosolic fraction of the mouse brain.
1.3. Methods for measuring sulﬁde in plasma or blood
The majority of measurements of blood sulﬁde have employed one
of two general methods, spectrophotometric measurement of methy-
lene blue formed from the reaction of sulﬁde with N-dimethyl-p-
phenylenediamine (NDPA) or sulﬁde anion (S2−) measurement with
an ion-selective electrode (ISE). Both methods almost exclusively use
plasma, not whole blood. Two common variations of the methylene
blue method are often used. In the original indirect method of
Stipanuk and Beck [63], and modiﬁed by Geng et al. [19], the sample is
placed in a closed container that also contains a ﬁlter paper wick. The
wick is saturated with an alkali such as zinc acetate but is not in
contact with the sample. Acid is added to the sample to drive all of the
sulﬁde into the gas phasewhere it is absorbed onto thewick. The wick
is then removed and mixed with the NDPA. Typically, 30–120 min is
allowed for gas evolution and absorption onto the wick. In the second,
“direct”, method, the NDPA and acid (such as trichloroacetic acid;
TCA) are added directly to the plasma to precipitate the plasma
proteins and immediately develop color.
Sulﬁde measurement with the ISE requires that all the sulﬁde is in
the form of S2−. This is accomplished by placing the sample in an
antioxidant buffer (AOB) comprised of a strong alkali and an
antioxidant (typical working strength: 0.5 mol/l sodium salicylate,
0.12 mol/l, ascorbic acid and 2.2 mol/l NaOH). Sulﬁde is usually
recorded 20–30 min after the plasma is mixed with the AOB (direct
method). In the indirect method, the sample is acidiﬁed and the
evolved H2S gas is carried in a stream of nitrogen into the AOB.
1.4. Potential problems with the methylene blue and ISE methods
Both the methylene blue and ISE methods employ harsh che-
mical conditions and there is considerable delay between blood
collection and sulﬁde measurement. It should also be noted that it is
Fig. 1. Continuous recording of sulﬁde in alkaline antioxidant buffer (AOB) using a
sulﬁde ion-selective electrode (ISE). Sulﬁdewas continuously generated from 5% bovine
serum albumin (BSA; solid line) in Kreb's buffer, but not from a 30 μmol/l sulﬁde
standard in BSA-free Kreb's buffer (dotted line). Removing the ISE from the BSA and
placing it in protein-free antioxidant buffer (blank) and returning it (second BSA) did
not affect the rate of sulﬁde formation and provided an estimate of the ISE response
time. Modiﬁed from [75], with permission.
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than plasma or blood. This avoids potential interfering substances,
but it does not accurately reproduce the blood/plasma environment.
Other potential problems are more speciﬁc to the individual
methods. The strong acidic conditions associated with the methy-
lene blue method suggest that if acid-labile sulﬁde is present in the
blood or plasma it would be liberated during the assay along with
free sulﬁde and artiﬁcially inﬂate the sulﬁde concentration. The
alkaline conditions of the AOB have been known to affect ISE
measurements in plasma since they were initially employed. Khan
et al. [33] observed that directly mixing blood and AOB resulted in
protein desulfuration and produced artiﬁcially elevated sulﬁde
values. In fact alkaline lability of protein sulfur has been known
for some time [5]. We [75] also observed that sulﬁde was produced
directly from bovine serum albumin in this alkaline environment. As
shown in Fig. 1, when a sulﬁde standard prepared in protein-free
buffer was placed in the AOB, the ISE recording was stable for 4 h.
However, when 5% bovine serum albumin (BSA; ∼plasma concen-
tration) was placed in AOB, the total sulﬁde measured with the ISE
rapidly increased for the ﬁrst 20 min and then continued to slowly
increase over the ensuing 3 h. The sulﬁde concentration in the BSA
solution estimated at the 20 min shoulder in Fig. 1 is around
100 μmol/l and this is within the range of sulﬁde concentrations
recorded in plasma samples in many studies over the past 10 years
(Table 1). After 3 h of incubation in AOB, the sulﬁde concentration
approached 6–7 mmol/l (Fig. 1). Assuming approximately 35
cysteine molecules per albumin molecule, the 5% BSA solution
would contain approximately 27 mmol/l cysteine sulfur. Thus in 3 h
this is equivalent to desulfurating nearly one-fourth of the Cys in
BSA. While albumin may contain a small quantity of sulfane sulfur,
it seems unlikely that this could account for the total sulﬁde
measured with the ISE. These ﬁndings suggest that much of the
sulﬁde measured with the ISE is derived from hydroxyl replacement
of cysteine sulfur in the albumin. Anecdotally, it was also noticed
that when HCl was added to the BSA/AOB several hours later to
lower the pH, the strong odor of H2S was immediately apparent.
1.5. Direct measurement of H2S gas with the polarographic HsS sensor
The recent development of a polarographic H2S sensor has provided
an alternative method for sulﬁde measurement [13,35]. This sensor,
patterned after the Clark type oxygen electrode, has an H2S-permeable
membrane, operates at a polarizing voltage well below that of O2 and
appears quite speciﬁc for H2S gas. The polarographic sensor permits thedirect measurement of H2S gas in biological ﬂuids without sample
modiﬁcation and in real-time [13,35,53,75]. Because the polarographic
sensor only measures H2S gas, sulﬁde (H2S gas, HS− and S2−) is
estimated indirectly from pH. Sensitivities as low as 15 nmol/l for H2S
(∼100 nmol/l sulﬁde) have been reported [75]. The ﬁndings from
recent studies using the polarographic sensor have begun to question
whether sulﬁdedoes indeed exist in the blood and if sulﬁde (orH2S gas)
is a physiologically relevant “gasotransmitter” in the circulation [75].
2. Evidence against free sulﬁde in the blood
2.1. Historical perspective
Fig. 2 summarizes the frequency of blood sulﬁde concentrations
reported over the past 29 years. It is evident that while studies prior to
2000 reported undetectable or minimal sulﬁde concentrations in the
blood, since 2000 there has been a tendency for steadily increasing
plasma sulﬁde values. Table 1 provides a chronological list of the sulﬁde
concentrations reported for plasma or blood over this period and the
method used. In the 11 studies from 1980 to 2000, 9 reported
undetectable levels of sulﬁde in the blood and the remaining 2 reported
2 and 6 μmol/l. In contrast, 30 of the 39 studies performed in the past
8 years have reported blood or plasma sulﬁde concentration between 3
and 300 μmol/l, with most in the 30–50 μmol/l range. It is also evident
from Table 1 that the high values for plasma sulﬁde are consistently
obtained using either the methylene blue method or the ISE.
As themethylene bluemethod involves strong acidiﬁcation, sulﬁde
measurements might be biased by the inclusion of acid-labile sulﬁde.
As shown in Table 1, there were 25 reports of blood or plasma sulﬁde
measurement since 2000 that employed either the direct or indirect
methylene blue method. Of these, there were 6 reports of plasma
sulﬁde levels ≥290 μmol/l, 11 studies reported sulﬁde levels between
20 and 60 μmol/l, and only 4 studies reported sulﬁde levels ≤
10 μmol/l. With the exception of studies by Whitﬁeld et al. [75] and
Sparatore et al. [61], the range of these measurements was from 8 to
301 μmol/l with an average of 121 μmol/l. In our study [75], the
average sulﬁde concentration measured in plasma from 6 vertebrates
using the indirect methylene bluemethodwas 2 μmol/l (ranging from
not detected to 4.3 μmol/l) and using HPLC analysis of methylene blue
Sparatore et al. [61] reported plasma sulﬁde b0.55 μmol/l.
There are approximately 15 reports of plasma sulﬁde concentra-
tionsmeasured using the ISE (Table 1). Of these, only one is in excess of
100, one is less than 30, and the average (excluding the high value) is
48 μmol/l.While there is less variation in these values compared to the
methylene bluemethod, it is possible that the veryalkaline antioxidant
buffer could release protein-bound cysteine sulfur (see above).
2.2. Radiolabeled 35S-sulﬁde
In two elegant, but apparently overlooked studies, Curtis et al.
[10] and Bartholomew et al. [1] examined the fate of 35S-labeled
sulﬁde in the rat and its consumption by blood and tissues. When
injected intravenously, less than 11% of the 35S-sulﬁde remained in
the blood after 5 min. 5 min after addition of 35S-sulﬁde to whole
blood in vitro, over 70% of the injected radionuclide was bound to
proteins with approximately half of the 35S bound to protein in the
plasma and the remaining half to protein in the red blood cells.
When 35S-sulﬁde was preincubated with whole blood and then
perfused through an isolated liver, the 35S-sulﬁde was rapidly
oxidized to 35S-sulfate leaving little free 35S-sulﬁde. 35S-sulﬁde
oxidation was also organ-speciﬁc being extremely rapid in the
perfused liver, less so in the kidney, and minimal in the perfused
lung. These results provide additional evidence that free sulﬁde does
not circulate in the blood and they also suggest that although
sulﬁde may transiently bind to blood proteins, it can be rapidly
unloaded and oxidized by organs such as the liver.
Table 1
Summary of studies reporting plasma or blood sulﬁde, listed chronologically.
Animal Method [Sulﬁde]
(μM)
Change in blood [sulﬁde] noted Lower detection
limit (μM)
Reference
Steer blood ISE indirect (METH) 2 N/A [33]
Wistar rat
blood
GC-ECD alk ext dx PFBBr,
(METH)
N/D N/A 0.3 [29]
Rat blood GC-EDC N/D [49]
human serum HPLC dx MBB, (METH)a N/D N/A 0.1 [67]
Rabbit blood GC-ECD alk ext dx PFBBr, N/D 500–1000 ppm by inhalation (lethal)=0.012 μmol/g, 200 ppm (non lethal)=N/D 0.3 [30]
Human
plasma
HPLC g.d., dx phen, (METH) N/D Added 1 and 5 μmoles in vitro, recovered most 0.03 [50]
Human serum HPLC dx DEAT, (METH)b 0.03 N/A [48]
Human blood Titrate with I2 microdist,
NaOH trap, (METH)
N/D Added 5, 10, 15 μg/50 ml, recovered all 0.13 [57]
Human bloodc GC-ECD alk ext dx PFBBr, N/D Plasma 7 and 30 μmol/l in fatal poisoning 0.3 [31]
SD rat serumd GC (none) N/D N/D after gas infusion into cecum ≤1 [38]
Human blood IC-ECD microdist, (METH) 2–6,
42,47,52e
No change when changing protein in diet [59]
SD rat plasma ISE 45.6 N/A [85]
Human blood GC–MS alk ext dx PFBBr,
(METH)
53.5 In vitro spiked baseline 53 μmol/l by additional 12.5, 25, and 37.5 μmol/l and
recovered most
[24]
Wistar rat
plasma
MB direct (none) 301 Drop to 192 in hypoxia, up to 317 in hypoxia+NaHS [81]
Wistar rat
plasma
? 38.6 Decreased ∼50% with L-NAME treatment [86]
Trout plasma ISE direct 38 N/A [14]
Trout plasma MB direct 40 N/A [14]
Wistar rat
plasma
MB indirect 60 Drop to ∼20 with isoproterenol treatment [19]
SD rat plasma MB direct 28.9 Increased to 37 after hemorrhage [46]
SHR rat
plasma
MB direct 20 Compare SHR to WKY control (below) [78]
WKY rat
plasma
MB direct 48 See above [78]
Wistar rat
plasma
MB direct 294 Drops to 196 in hypoxia, up to 323 in hypoxia+NaHS, down to 142 in hypoxia+PPG [84]
Human
plasma
ISE direct 34 55% higher in stable COPD patients [9]
Wistar rat
plasma
MB direct 290 Increased to 369 in 45.2 2 °C temperature-induced seizures, decreased to 126 with
seizures+HA, increased to 456 with seizures and NaHS
[22]
Human
plasma
ISE direct 51.7 Decreased to 26 in heart disease [27]
Mouse plasma MB direct 34 Increased to 41 6 h after LPS, and 65 24 h after LPS [40]
Human
plasma
MB direct 43.8 Increased to 150 in humans with septic shock [40]
SD rat plasma MB direct 40 Decreased to 38 with streptozocin (stz) treatment and increased to 42 with stz+insulin [80]
Wistar rat
plasma
ISE indirectf 47 Decreases to ∼37 with colorectal distension (i.e. pain), 29 with i.p. NaHS, 18 with
NaHS+L-NAME
[12]
Human child
plasma
ISE direct 65 Decreased to 52 in children with essential hypertension [11]
Wistar rat
plasma
MB direct 298 Decreases to 195 with hypoxia, 271 with i.p. NaHS+hypoxia [28]
Rat MB direct 274–295 [21]
SD rat plasma ISE 29 “H2S solution” increased to 40, hyperhomocysteinemia increased to 50 [6]
Human child
plasma
ISE direct 52 N/A [7]
SD rat blood PH2SS ≤5 N/A [34]
Sw. alb. mouse
plasma
MB direct 8 Increases to 20 with cecal ligation/puncture [82]
Wistar rat
plasma
MB direct 38 Increased after myocardial infarction as follows (all i.p.): vehicle 57, PPG 39, NaHS 92 [87]
Trout whole
blood
PH2SS N/D Drops to 0.3 after 10 10 μmol/l sulﬁde spike 0.015 [75]
Trout plasma MB direct 3 [75]
Mouse whole
blood
PH2SS N/D Drops to 0.5 after 10 10 μmol/l sulﬁde spike 0.015 [75]
LW rat whole
blood
PH2SS N/D Drops to 0.4 after 10 10 μmol/l sulﬁde spike 0.015 [75]
LW rat plasma MB direct N/D [75]
HSD rat whole
blood
PH2SS N/D 0.015 [75]
HSD rat plasma MB direct 4 [75]
Pig whole
blood
PH2SS N/D Drops to 0.3 after 10 10 μmol/l sulﬁde spike 0.015 [75]
Pig plasma MB direct 2 [75]
Cow whole
blood
PH2SS N/D Drops to 0.4 after 10 10 μmol/l sulﬁde spike 0.015 [75]
(continued on next page)
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Table 1 (continued)
Animal Method [Sulﬁde]
(μM)
Change in blood [sulﬁde] noted Lower detection
limit (μM)
Reference
Cow plasma MB direct 2 [75]
Trout blood
in vivo
PH2SS N/D Drops to 0.2 after 30 30 μmol/l injection 0.015 [75]
Trout blood
in vivo
PH2SS N/D No change after hypoxia 0.015 [53]
Trout blood ISE direct 391 Hypoxia inc to 1 mmol/l [53]
Mouse serum
CSE+/+
ISE direct 41 [79]
Mouse serum
CSE−/+
ISE direct 33 [79]
Mouse serum
CSE−/−
ISE direct 17 [79]
Rat plasma MB indirect 33, 47 [42]
Rat plasma ISE direct 31 Ovalbumin inc to 72, ova+i.p. NaHS 40 [8]
Rat plasma MB/HPLC 0.55 1.42 with H2S-releasing asprin [62]
Human
plasma
? 45 Alzheimer's=34, vascular dementia=36, cerebrovascular disease=37 [44]
Mouse plasma MB direct 10 +PPG=13, cecal puncture puncture=20, puncture+PPG=13, sham=14 [83]
Rat plasma ISE direct 37 Oeloc acid=20, oelic acid+NaHS=27 [43]
Rat plasma MB direct 300 Hypoxia=187, hypoxia+NaHS=317 [74]
Zucker rat
plasma
ISE direct 48
(lean)
Diabetic=68, fatty=48, after PPG all ∼20 [77]
Mouse ISE direct 58 ApoE−/−45, AopE−/−+NaHS=52, ApoE−/−+PPG=36 [72]
Trout plasma ISE direct 90 Hypoxia=420 [55]
Rat plasma MB/HPLC b0.55 [61]
Summary does not include studies that involve cases of lethal sulﬁde poisoning or inwhich the reductant dithiothreitol was added to the sample prior to analysis. Concentrations are
control values unless noted. Question mark in the “Method” column, method not clear or unavailable.
Abbreviations: alk ext, alkaline extraction; dx DEAT, derivatization of 2-amino-5-N,N-diethylamino toluene to thionine; dx MBB, derivatization of monobromobimane to ﬂuorescent
sulﬁde derivative; dx PFBBr, derivatization of pentaﬂuorobenzyl bromide to bis(pentaﬂuorobenzyl)sulﬁde; dx phen, derivatization of p-phenylenediamine to thionine; METH., paper
is describing a new method for measuring sulﬁde in blood or plasma; ECD, electrochemical detector; GC-ECD, gas chromatography-electron capture detector; GC–MS, gas
chromatography–mass spectrometry; g.d., gas dialysis; HA, hydroxyl amine, cystathionine β-sythase inhibitor; HPLC, high performance liquid chromatography; IC, ion
chromatography; ISEdirect, sulﬁde ion-selective electrode, sample is added directly to antioxidant buffer; ISEindirect, sulﬁde ion-selective electrode, sample is acidiﬁed and H2S
carried to antioxidant buffer in a stream of N2; LPS, lipopolysaccharide-induced inﬂammation; MBdirect, methylene blue, sample is added directly to assay reagents; MBindirect,
methylene blue, H2S is liberated from sample by acid, trapped as ZnS on ﬁlter paper and added to assay reagents; MB/HPLC, methylene blue, high performance liquid
chromatography;microdist, microdistillation; N/D, not detected; PH2SS, polarographic hydrogen sulﬁde sensor; PPG, propargylglycine, cystathionine γ-lyase inhibitor; SD, Sprague–
Dawley; SHR, spontaneously hypertensive rat; Sw. alb., Swiss albino; WKY, Wistar–Kyoto.
Superscripts:
a Plasma was ultraﬁltered 15 min before assay.
b Let blood stand for 2 h before taking serum.
c Blood came from patients with non-fatal sulﬁde poisoning.
d Cecum was inﬂated with H2S gas during blood draw.
e Six values of 2–6 μM were listed in a table while 42, 47, and 52 μM were reported in the text. The reason for the difference was not clear.
f Add NaOH to sample prior to acidiﬁcation, which could lead to desulfuration of protein as in direct ISE method. Modiﬁed from [75], with permission.
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In a recent study, we [75] used the polarographic H2S sensor to
measure sulﬁde in plasma and blood from a variety of vertebrates.
This study failed to ﬁnd evidence that H2S gas exists in the blood or
plasma at the level of sensitivity of the sensor (15 nmol/l) and it
appeared that exogenous sulﬁde was in fact consumed by blood in
vitro (Fig. 3). In addition, this [75] and another study [53] ﬁtted
rainbow trout with an extracorporeal loop and pumped blood from
either the dorsal (post-gill) or ventral (pre-gill) aorta of unanesthe-
tized ﬁsh across a thermo-jacketed polarographic sensor and
returned it into the caudal vein. Both studies failed to detect sulﬁde
in the blood. Furthermore, injection of exogenous sulﬁde into the
ﬁsh produced a transient spike in blood sulﬁde but this returned to
baseline within 30 min (Fig. 4; [75]).
It is interesting to note that in a study of a novel water-soluble
H2S-releasing molecule, GYY4137, Li et al. [42] used the polaro-
graphic H2S sensor to measure release of sulﬁde from GYY4137
when the GYY4137 was dissolved in phosphate buffer, whereas, they
used the methylene blue/zinc acetate trapping method to measure
sulﬁde in plasma. It is not clear why these two different methods
were used. Li et al. [42] also observed that an intravenous injection
of 20 μmol NaHS per kilogram did not signiﬁcantly increase plasma
sulﬁde 30 or 180 min after injection (measured with the methyleneblue method). However, six other studies that employed the
methylene blue method (Table 1) reported that intravascular or
intraperitoneal injection of sulﬁde increased plasma sulﬁde (all but
one of these reported control plasma sulﬁde levels was in excess of
200 μmol/l).
2.4. Anecdotal evidence
A number of other early reports anecdotally and experimentally
support rapid consumption of sulﬁde by blood in vivo and in vitro and
they suggest that free sulﬁde levels are indeed very low. In pioneering
studies, Haggard [20] showed that if 10 ml of 77 mmol/l Na2S was
rapidly injected into a dog it was invariably lethal whereas ﬁve times
that dose could be injected if given over a 20 min period and the
animal was “apparently none the worse.” Haggard concluded that
sulﬁde was rapidly detoxiﬁed, presumably through metabolism. Prior
et al. [56] observed that LC50 (concentration at which 50% of the
subjects died) for H2S inhaled by rats was 335 ppm over 6 h of
exposure while the LC10 over the same time was 299 ppm. Assuming
that H2S readily equilibrates across the alveolar membranes, this
would produce sulﬁde values in the plasma of 157 μM and 143 μM,
respectively (calculations in [75] “supplementary material”). In fact,
Prior et al. [56] suggested that the steepness of the dose–response
curve was due to an overload of the sulﬁde detoxiﬁcation system,
Fig. 4. Real-time measurement of plasma sulﬁde in an unanesthetized rainbow trout
ﬁtted with an extracorporeal loop (A). Blood was pumped from a cannula inserted into
the dorsal aorta across a thermo-jacketed polarographic H2S sensor and returned to the
Fig. 2. Frequency distribution of recorded sulﬁde concentrations in blood from different
vertebrates over the past 30 years. Bars indicate the range of sulﬁde concentration in
μmol/l. ⁎, 8 of the 9 values less than 1 μmol/l reported in 2008–2009 were obtained
using the polarographic H2S sensor. Note the trend for increasing plasma sulﬁde values
over the past 10 years.
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detoxiﬁed. Given this capacity to metabolize sulﬁde, it is difﬁcult to
imagine that therewould be any opportunity for sulﬁde to accumulate
under resting conditions. It is also clear that H2S can leave the blood
across the alveolar membrane, as intravenously injected NaHS was
partially recoverable as H2S in exhaled air [17]. If 10 μM sulﬁde in
plasma was in equilibrium with alveolar gas, H2S should be readily
detectable by smell in exhaled air where its concentration would be
22 ppm. Clearly it is not noticeable. Moreover, the reported levels ofFig. 3. Polarographic measurement of exogenous sulﬁde (Na2S) consumption by whole
blood from trout (A), Harlen–Sprague–Dawley rat (B) or 5% bovine serum albumin
(BSA) in Kreb's buffer (C). Each spike represents enough Na2S to raise total sulﬁde
10 μmol/l, i.e., trout blood will increase to100 μmol/l, rat blood to 20 μmol/l and BSA to
10 μmol/l if there was no sulﬁde consumption. Inset in (C); sulﬁde added to Kreb's
buffer without protein remains in the solution but is rapidly removed by the addition of
excess Zinc acetate (Zn; ﬁnal concentration 450 μmol/l). (D); sulﬁde consumption in
BSA increases with increasing protein concentration and is independent of the presence
of oxygen (open bars equilibrated with 95% air/5% CO2, closed bars equilibrated with
95% N2/5% CO2; all n=4). Modiﬁed from [75], with permission.
ﬁsh via the caudal vein (shown schematically in B). Sulﬁde estimated from H2S gas
measurement and blood pH (7.8) of resting trout was ∼0.1 μmol/l. At 3 min (arrow)
exogenous sulﬁde (as Na2S), theoretically sufﬁcient to raise plasma sulﬁde to 30 μmol/l
when fully mixed in the plasma, was injected as a single bolus into the caudal vein.
Following injection, plasma sulﬁde increased to ∼1.5 μmol/l and rapidly returned to
baseline. These results show that circulating sulﬁde in trout blood is essentially nil and
when exogenous sulﬁde is injected into the vasculature it does not remain in the
circulation longer than a fewminutes. Inset: injection of the same amount of sulﬁde into
a recirculated volume of physiological buffer equivalent to the trout's plasma volume
and pH. Sulﬁde concentration remains stable for 15 min until washed away (W). (A),
modiﬁed from [75], with permission.H2S in human exhaled [47] and end-expiratory [64] air are only
∼50 ppb, more than 400-fold less than predicted.
3. Evidence against labile sulﬁde transport in blood
We have used a variety of procedures to determine if sulﬁde
consumed by blood is incorporated into a labile pool and/or if this is a
methodological artifact. Using the direct methylene blue method, we
measured sulﬁde inwhole blood and plasma spikedwith Na2S [75]. As
shown in Table 2, if plasma is spiked with sulﬁde (as Na2S) after
acidiﬁcation and centrifugation, essentially all of the sulﬁde in the
spike is recovered. However, if the sulﬁde is added to whole bloodTable 2
Acid-labile sulﬁde and sulﬁde recovery from fresh plasma and Na2S-spiked plasma or
spiked whole blood assayed with the direct methylene blue method.
Plasma Spike Spiked plasma Spiked blood N
Lamprey 2.6±0.6 10 10.2±0.6 1.2±1.0 4
Trout 1.6±0.5 10 10.8±0.5 2.0±0.1 8
HSD rat 4.3±0.5 10 10.4±0.7 NM 6
Pig 2.3±0.2 10 8.6±0.2 1.5±0.1 4
Cow 2.1±0.4 10 9.4±0.8 1.1±0.1 4
Mean±SE, N=number of animals; NM, not measured. Na2S was added to plasma after
centrifugation and acidiﬁcation and to whole blood prior to centrifugation and
acidiﬁcation. In both instances the amount of Na2S should theoretically increase the
sulﬁde concentration by 10 μmol/l. Adapted from [75], with permission.
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These studies suggest that sulﬁde is rapidly consumed bywhole blood
(which conﬁrms the measurements with the polarographic H2S
sensor, see above) and that the added sulﬁde does not become part
of an acid-labile pool. Similar ﬁndings have recently been reported by
Sparatore et al. [61].
To determine if exogenous sulﬁde could be absorbed by blood and
then released by the antioxidant buffer, we incubated trout blood for
30 min after being spiked with an amount of NaHS calculated to
produce a theoretical increase in sulﬁde concentration of 50, 100 and
250 μmol/l [53]. Sulﬁde concentrations in the spiked samples were 0,
5 and 88 μmol/l suggesting that the exogenous sulﬁde was not
incorporated into an alkaline-labile sulfur pool and that some of the
exogenous sulﬁde was actually removed from the free sulﬁde pool.
Because these samples were not aerated it is unlikely that the sulﬁde
was lost as H2S gas and more likely that it was oxidized.
4. Is there a “history” of sulﬁde in the blood?
In spite of the experimental and anecdotal evidence that H2S gas or
sulﬁde does not circulate in vertebrate blood, the numerous reports
that a variety of experimental protocols appear to signiﬁcantly affect
plasma or blood sulﬁde concentrations (Table 1) is particularly
disconcerting. Does this suggest that all of these results are experi-
mental artifact? Or, do these results collectively suggest that sulﬁde is
carried in some formother than either acid-labile or sulfane sulfur, that
this unknown form can be detected by both methylene blue and ISC
methods, and that this provides a history of past sulﬁde production?
Obviously, resolution of this question is of paramount importance in
evaluating the biological and potentially clinical signiﬁcance of sulﬁde.
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